Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 5/20 | 0.37 |
| ▸ | ACHE | P22303 | 5/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653428 | 0.86 | CRBN (0.55) | DDB1CRBNBCHEACHELMNA | |
| SCHEMBL12638511 | 0.85 | CRBN (0.45) | DDB1CRBNBCHEACHELMNA | |
| SCHEMBL23979598 | 0.83 | CRBN (0.49) | DDB1CRBNBCHEACHELMNA | |
| SCHEMBL26192650 | 0.79 | NAMPT (0.45) | NAMPT | |
| SCHEMBL18595132 | 0.76 | CRBN (0.55) | DDB1CRBNNPSR1KDM4EHPGD | |
| SCHEMBL13806967 | 0.76 | CRBN (0.55) | DDB1CRBNNPSR1KDM4EHPGD | |
| SCHEMBL26192453 | 0.76 | CRBN (0.55) | DDB1CRBNNPSR1KDM4EHPGD | |
| SCHEMBL16221487 | 0.75 | CRBN (0.56) | DDB1CRBNNPSR1KDM4EHPGD | |
| SCHEMBL12638502 | 0.75 | DDB1 (0.45) | DDB1CRBNNPSR1KDM4EHPGD | |
| SCHEMBL15362536 | 0.75 | DDB1 (0.45) | DDB1CRBNNPSR1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277539-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX LLC (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277539-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | AQP3, AQP4, AQP1 | DDB1 3771/4885CRBN 2849/4885BCHE 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.